Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OL-101 in Relapsed or Refractory Multiple Myeloma
NCT06644118Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OL-101 in multiple myeloma (MM), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment emergent adverse event at 1 year. Started Oct 2024; status: recruiting.
02
Drugs
OL-101
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06644118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644118.